Warner Chilcott Limited today [1-7-2009] announced that it has signed an agreement with Dong-A PharmTech Co. Ltd., based in Korea, to develop and market their orally-administered udenafil product, a phosphodiesterase type 5 (PDE5) inhibitor for the treatment of erectile dysfunction (ED) in the United States. Dong-A has successfully completed Phase 2 studies of the product in the United States.Got that? Vi*agra is about to get a new competitor, developed by a company named Dong-A.
I can only assume it means something different in Korean.
Mind you, I'm not mocking the product at all. It's reportedly effective but may have fewer side effects than Vi*agra. That could be a real boon to the substantial number of men who give up PDE5 inhibitors because they get spooky vision changes, severe headaches, or other untoward symptoms.
In the meantime, I bet some enterprising pharma company is working its way up toward Willie-Z.